Please use this identifier to cite or link to this item:
http://localhost:8080/xmlui/handle/123456789/8634
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wardhani, Sofia | - |
dc.contributor.author | Aryati, Aryati | - |
dc.contributor.author | urwanto, Bambang P | - |
dc.date.accessioned | 2024-11-30T03:17:14Z | - |
dc.date.available | 2024-11-30T03:17:14Z | - |
dc.date.issued | 2024-09 | - |
dc.identifier.citation | Research Article | en_US |
dc.identifier.uri | http://localhost:8080/xmlui/handle/123456789/8634 | - |
dc.description.abstract | Background: The effect of HBO2 alone on Sirt-1 and Syndecan-1 is unknown, even though both molecules are involved in preventing endothelial dysfunction. This study aims to determine the effect of HBO2 on Sirt-1 and Syndecan-1 as therapeutic targets for endothelial dysfunction. Method: This study employed a true experimental post-test design. Twenty male Sprague Dawley rats aged 12-14 weeks were divided into two groups. Diving was carried out in an animal hyperbaric chamber with a dose of 2.4 ATA for 60 minutes. All data were collected 18 hours after diving. Results: Our study revealed that the administration of HBO caused an increase in serum MDA and endothelial NF-kB levels (p = 0.007; p = 0.001, respectively) without an increase in any inflammatory markers, specifically IL-1 and VCAM-1 levels (p = 0.707; p = 0.168, respectively). HBO2 decreased Syndecan-1, a marker of endothelial injury (p = 0.026), but did not affect endothelial eNOS and Sirt-1. Conclusion: HBO2 did not cause endothelial injury and inflammation, but the dose used was not enough to increase Sirt-1 levels. Additional research is needed to determine a hormesis dose that can increase Sirt-1 levels. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | Pharmacognosy Journal | en_US |
dc.subject | Sirt-1 | en_US |
dc.subject | Syndecan-1 | en_US |
dc.subject | HBO2 | en_US |
dc.subject | Endothelial dysfunction | en_US |
dc.title | The Effect of HBOT on SIRT-1 and SYNDECAN-1 as Therapeutic Targets for Endothelial Dysfunction | en_US |
dc.type | Article | en_US |
Appears in Collections: | VOL 16 NO 5 2024 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1090-1095.pdf | 183.83 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.